Pfizer, Inc. (PFE)
A research-based, pharmaceutical Company which discovers, develops, manufactures and markets prescription medicines for humans and animals.
Recs
Well-run and cash-rich.. Demographics favor this company.
Recs
Changes in reimbursement as health care costs are rationalized.
Recs
value, dividend
Recs
Cake Dex test run
Recs
After healthcare reforms the pimps will be gone and the benefit will go to the patients and indirectly to the pharmacuticals
Recs
Recs
it is viagra for the S&P500
Recs
good company, meds for boomers, always chance for block buster drug
Recs
I actually bought this stock under $16.50 months ago and have been waiting for this acquisition to take place. Right now everything is in place for this stock to break the $20 range by end of year. Plus they have a solid dividend that is not going anywhere anytime soon
Recs
Awesome company with 15 plus pending FDA approval for drugs.
Recs
Flu epidemic. Current proposal to FDA over HIV medicine.
Recs
This account tracks the performance of the investment firm Ruane, Cunniff, and Goldfarb - the investment manager of Sequoia Fund.
Recs
global name known for decades and their research will get this stock ahead of their competitors
Recs
Can't say I'm too thrilled with the prospect of a $2.3 billion fine for shady quid pro quo business practices. But nevertheless people need drugs and Pfizer has the line up. Hopefully, the drug pipeline from Wyeth will make up for expiring patents from Lipitor in 2011. Let's just hope they don't try to market the next Thalidomide or something.
Recs
The Wyeth acquisition will probably weigh down the stocks for a while, but gaining that pipeline of potential drugs and product should pay off in a couple of years. The management also seems to be devoted to streamlining research and development and to focusing on high-potential projects.
Recs
worked for the company for 28 years
Recs
astounding balance sheet
Recs
Drug companies manufacture money in the form of little pills. The population is getting older and needs more pills to keep going, ergo: more money for Pfizer.
Recs
Low P/E, solid company, getting very little value placed on the current pipeline. Looks reasonable timing on a technical basis too, having recently broken above the 200 day mva.
Recs
good fundamentals

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 940 1 2 3 4 5 6 7 8 9 10 Next »